Calliditas therapeutics

Calliditas

This biopharmaceutical company develops and commercialises treatments for orphan indications, including medicine for patients with primary immunoglobulin A nephropathy.

Chinook Therapeutics

This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

Abliva

This biopharmaceutical company develops novel medicines for patients suffering from rare and severe primary mitochondrial diseases.

OxThera AB

This biopharmaceutical company develops bacteria-based therapies to treat patients with primary hyperoxaluria and other rare kidney diseases.

River Renal

This clinical-stage biotechnology company develops novel pharmaceutical therapies targeting orphan renal diseases for patients with unmet medical needs.

Calluna Pharma

This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.

Cereno Scientific

This biotech company develops epigenetic therapies for patients with rare cardiovascular and pulmonary diseases.